Form 4 for IDXX Idexx Laboratories
Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-06 · accession 0000874716-24-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-07 | 2024-03-06 | IDXX | POLEWACZYK JAMES F | EVP | S - Sale+OE | $558.44 | -8,104 | 10.7K | -43% | -$4.53M |
| DM | 2024-03-07 | 2024-03-06 | IDXX | POLEWACZYK JAMES F | EVP | M - OptEx | $422.45 | +8,104 | 11.5K | +241% | +$3.42M |
| DM | 2024-03-07 | 2024-03-06 | IDXX | POLEWACZYK JAMES F | EVP | M - OptEx | $0.00 | -8,104 | 1,363 | -86% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-06 | S | D | 3,290 | $558.88 | 11,391.23 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2024-03-06 | S | D | 4,134 | $557.94 | 14,681.23 | D | — | — | (F1) Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 3 | Common | Common Stock | 2024-03-06 | M | A | 4,640 | $544.08 | 18,815.23 | D | — | — | |
| 4 | Common | Common Stock | 2024-03-06 | M | A | 2,226 | $288.78 | 14,175.23 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-06 | M | A | 483 | $206.94 | 11,949.23 | D | — | — | |
| 6 | Common | Common Stock | 2024-03-06 | S | D | 680 | $559.33 | 10,711.23 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 7 | Common | Common Stock | 2024-03-06 | M | A | 755 | $206.94 | 11,466.23 | D | — | — | |
| 8 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2024-03-06 | M | D | 755 | $0.00 | 0 | D | $206.94 · — to 2029-02-13 | 755 Common Stock | (F4) Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |
| 9 | Derivative | Incentive Stock Option (right-to-buy) | 2024-03-06 | M | D | 483 | $0.00 | 0 | D | $206.94 · — to 2029-02-13 | 483 Common Stock | (F5) Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. |
| 10 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2024-03-06 | M | D | 2,226 | $0.00 | 0 | D | $288.78 · — to 2030-02-13 | 2,226 Common Stock | (F6) Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. |
| 11 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2024-03-06 | M | D | 4,640 | $0.00 | 1,363 | D | $544.08 · — to 2031-02-13 | 4,640 Common Stock | (F7) Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022. |